Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Hepatocellular Carcinoma Patients Treated with Atezolizumab and Bevacizumab

Gastrointestinal Cancer

Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death

Clin Cancer Res

Cabibbo G, Celsa C, Battaglia S, Enea M, Di Maria G, Grova A, Ciccia R, Manfredi GF, Iavarone M, Vogel A, Singal AG, Reig M, Pinato DJ, Cammà C

doi: 10.1158/1078-0432.CCR-24-2582

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Genitourinary Cancer

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Cancer Treat Rev

Zhang Y, Chen J, Liu H, Dai J, Zhao J, Zhu S, Zhang X, Liang J, Hu X, Zhao J, Liu Z, Shen P, Sun G, Zeng H

doi: 10.1016/j.ctrv.2024.102787

Head and Neck Cancer

Antihypertensive drugs and survival outcomes in oropharyngeal squamous cell carcinoma patients

J Natl Cancer Inst

Lee CM, Wadsworth BJ, Urban R, Clark MA, Shi R, Sit D, Hamilton SN, Bennewith KL

doi: 10.1093/jnci/djaf056

Breast Cancer

Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials

Eur J Cancer

Hart LL, Im SA, Tolaney SM, Campone M, Pluard T, Sousa B, Freyer G, Decker T, Kalinsky K, Sopher G, Gao M, Hu H, Kuemmel S

doi: 10.1016/j.ejca.2025.115225

Gastrointestinal Cancer

Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes

Eur J Cancer

Fortuny M, García-Calonge M, Arrabal Ó, Sanduzzi-Zamparelli M, Castaño-García A, Cascos E, Mesa A, Piedra-Cerezal AM, Llarch N, Iserte G, Campos M, González M, Marsal A, Lorca R, Rodríguez M, Torres F, Varela M, Reig M

doi: 10.1016/j.ejca.2025.115404

Lung, Respiratory and Thoracic Cancer

Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy

Eur J Cancer

Monaca F, Gomez-Randulfe I, Parreira AS, Longo V, Galetta D, Pilotto S, Polidori S, Cantale O, Stefani A, Vita E, Taylor P, Gomes F, Cove-Smith L, Summers Y, Tortora G, Blackhall F, Novello S, Bria E, Califano R

doi: 10.1016/j.ejca.2025.115435

Lung, Respiratory and Thoracic Cancer

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

Lung Cancer

Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, de Castro G Jr, Havel L, Bernabé Caro R, Losonczy G, Lee JS, Kowalski DM, Andric Z, Califano R, Veatch A, Gerstner G, Batus M, Morris S, Kaul M, Cuchelkar V, Li H, Danner BJ, Nabet BY, Liu SV

doi: 10.1016/j.lungcan.2024.107924

Gastrointestinal Cancer

Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

J Clin Oncol

Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta C, Abraham J, McCoy CL, Patel N, Negro A, Vogel A, Abou-Alfa GK

doi: 10.1200/JCO.23.01462

Related content

Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Antihypertensive drugs and survival outcomes in oropharyngeal squamous cell carcinoma patients

Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials

Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes

Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma